Q4 2025 earnings call: ivonescimab Phase III updates, FDA PDUFA timeline, interim PFS in Q2 2026, cash position—read now.

Anifrolumab yielded positive outcomes, including remission in 26% of patients, at 6 months across a real-word, multicenter cohort of patients with systemic lupus erythematosus, according to data ...

6 Health and Social Research Center, Universidad de Castilla La-Mancha, Cuenca, Spain Objective To examine the predictive validity of field-based muscular strength tests in relation to incident ...

BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma Early-phase clinical trials (EPCTs) have been ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the fourth quarter and ...

Background We describe the occurrence of second primary lung cancers (SPLCs) and their determinant in Sweden. Methods Nation-wide cancer registry from years 1961 to 2021 identified a total of 853 ...

A new analysis from the 2015 Pelotas Birth Cohort suggests that dietary patterns at just 2 years of age are associated with ...

Introduction Onchocerciasis, commonly known as river blindness, is a parasitic disease caused by Onchocerca volvulus affecting millions predominantly in sub-Saharan Africa. Robust epidemiological ...

Objectives Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections ...